Key facts
- iRegene’s last known valuation is $568.6M (Apr 2025).
- It has raised $392.8M; the latest was Later Stage VC ($41.9M) in Sep 2025.
- Notable investors include Northern Light Venture Capital, Vertex Ventures China, GSR United Capital, Orinno Capital, Lotus Lake Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for iRegene
- ·The full record, as it builds
Funding rounds
No funding rounds for iRegene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iRegene
Developer of chemically-derived allogeneic cell therapies aims to provide first-in-class treatments for major degenerative diseases. The company leverages proprietary platforms and a pipeline led by NouvNeu001 for Parkinson's Disease to serve patients with conditions such as retinal degeneration and ischemic stroke, enabling faster-acting, disease-reversing therapeutic options.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2017
- Employees
- 62
- Website
- cn.iregene.com/
- Ownership
- Privately Held (backing)
iRegene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iRegene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iRegene in its N-PORT filings yet. We sweep new filings monthly.